Topic Listing for Tercica

Accounting Income Taxes Accounting Tax Considerations
Accrued Expenses Accrued Liabilities
Acquired In-process Research Development Action Without Meeting
Active Pharmaceutical Ingredient Specifications Additional Information Merger Find
Additional Information Proposed Merger Transaction Find Additional Information Proposed Transaction Find
Additional Rights Terminate Insmeds Material Breach Such Respect Additional Shares Common Stock Shall Meaning Assigned
Address Including Zip Code Telephone Number Area Registrants Address Principal Executive Offices Including Zip Code
Adjourned Meeting Notice Adjournment
Adjustment Provisions Administration
Advance Notice Director Nominations Advance Notice Stockholder Business
Advancement Expenses Advantages
Affiliation Agreement Affirmative Covenants
Aggregated Option Exercises Last End Values Agreement Plan Merger
Agreement Plan Merger Ipsen Ajay Bansal
Ajay Bansal-chief Financial Officer Senior Vice President Finance Ajay Bansal-executive Vice President Chief Financial Officer
Alexander Barkas Phd Als Credit
Alternative Dispute Resolution Amended Restated 2004 Stock Plan
Amended Restated Investors Rights Agreement Amendment
Amendment Executive Employment Agreements Amendment Existing Igf-1 Agreements
Amendment Initial Indication Igf-1 Agreement Amendment Key Employee Agreement
Amendment Lease Amendment License Collaboration Agreement
Amendment Offer Letter Amendment Registration Rights Agreement
Amendment Repeal Amendment Termination Plan
Amendments Amendments Articles Incorporation Bylaws Change
Amendments Manufacturing Services Agreement Amendments Waivers
Amortization Intangible Assets Andrew Grethlein
Andrew Grethlein Phd Andrew Grethlein Phd-senior Vice President Pharmaceutical Operations
Annex Annual Cash Bonus Awards
Annual Meeting Annual Meeting Stockholders Held 2006
Annual Statement Stockholders Another Overcomes Orphan Drug Marketing Exclusivity Obtains Europe
Another Party Obtains Orphan Drug Pediatric Exclusivity Rhigf-1 Anti-takeover Provisions Charter Documents Delaware Law Make Acquisition
Appointment Initial Investor Directors Appraisal Rights
Approval Adoption Rights Agreement Approval Majority Charter Amendment
Approval Milestone Payments Approval Supermajority Charter Amendments
Assignment Assumptions
Attached Atters Equiring Nvestor Pproval
Attestation Report Registered Public Accounting Firm Attorneys Genentech Inc
Attorneys Insmed Incorporated Celtrix Pharmaceuticals Inc Therapeutic Proteins Attorneys Tercica Inc
Audit Committee Authorization Indemnification
Authorized Signatures Sign Here Completed Instructions Executed Available Information
Awards Granted 2007 Current 2004 Plan Awards Granted Non-employee Directors Amended 2004 Plan Annual
Ayment Onversion Ote Background
Background Purpose Plan Background Reasons Rights Agreement
Balance Sheet Details Base Salaries
Basis Presentation Beneficial Owner Shares Registered Name Broker Bank
Beneficial Ownership Reporting Compliance Benefits
Bjectives Board Committee Action Unanimous Written Consent Without Meeting
Board Directors Board Directors Recommends Vote Nominees Director Listed Proposal
Board Directors Recommends Vote Proposal Below Board Observer Rights
Books Records Budgetary Cash Constraints Force Delay Efforts Develop Certain
Budgets Calculation Royalty Due Payable Licensor Licensee
Canada Iplex Sales Tercica Genentech Indications Cash
Cash Compensation Arrangements Cash Equivalents Short-term Investments Restricted
Cash Flow Ceo Ermination Onsultation
Certain Definitions Certain Provisions Tercicas Certificate Incorporation Bylaws
Certain Relationships Related Transactions Certain Restrictions
Certificates Certification
Cgmp Activities Chairman Board
Change Estimated Fair Value Embedded Derivative Change Vote After Submitting Proxy
Changes Capital Structure Changes Control
Changes Internal Control Over Financial Reporting Changes Results Reported Earnings
Charter Amendment Charter Amendments Rights Plan
Check Appropriate Box Below Form 8-k Filing Intended Checking Non Conformity
Checks Drafts Evidences Indebtedness Chief Executive Officer
Chief Financial Officer Chris Rivera
Christophe Jean Claims
Claims Concerns Arise Regarding Safety Efficacy Increlex Require Claims Concerns Arise Regarding Safety Efficacy Products Require
Class Shares Clinical Development Long Expensive Uncertain Process Delay Failure
Clinical Trial Expenses Code Business Conduct Ethics
Collaboration Ipsen Limits Ability Enter Transactions Pursue Opportunities Combination Product Development Commercialization Agreement
Combination Product Igf-1 Together Recombinant Human Growth Hormone Combination Products Agreement Genentech
Commercial Diligence Commercialization
Commercialization Responsibilities Commitments
Commitments Contingencies Committed Equity Financing Facility
Committed Equity Financing Facility Entered Kingsbridge Capital Limited Committed Equity Financing Facility Entered Kingsbridge Not Available
Committed Equity Financing Facility Entered Kingsbridge Result Dilution Committed Equity Financing Related Warrant
Committees Committees Directors
Common Stock Common Stock Agreement Hereby Deleted Shall Further
Common Stock Purchase Agreement 2007 Etween Common Stock Purchase Agreement 2008 Etween
Companies Partner Through License Development Agreement Comparable Analysis
Comparable Fund Raising Analysis Comparable Transaction Analysis
Compared 2002 Compared 2003
Compared 2004 Compared 2005
Comparison 2006 2007 Compensation
Compensation Chief Executive Officer Compensation Committee
Compensation Committee Interlocks Insider Participation Compensation Committee Processes Procedures
Compensation Committee Report Compensation Decisions
Compensation Directors Compensation Executive Officers
Compensation Information Executive Officers Compensation Officers
Compensation Philosophy Compensation Survey
Competition Competitors Challenge Patents Abbreviated New Drug Application Anda
Competitors Develop Gain Fda Approval Products Containing Rhigf-1 Competitors Develop Gain Fda Approval Rhigf-1 Adversely Affect
Compliance Securities Laws Comprehensive Income Loss
Comprehensive Loss Compulsory Acquisition
Computershare Trust Concentration Credit Risk
Concentration Limits Concentrations
Conditions Closing Conditions Issuance Shares
Conditions Milestone Closing Conditions Obligation Investor Accept Draw Down
Conditions Option Closing Conduct Business
Conference Call Begins 430 Eastern Time Today Conference Call Information
Conference Call Webcast Information Confidentiality
Confidentiality Publicity Consent Independent Registered Public Accounting Firm
Consent Waiver Amendment Constitution Powers
Construction Definitions Contact
Contact Information Contacts
Contents Contingencies
Contract Manufacturers Facilities Operations Not Achieve Satisfactory Cgmp Contract Manufacturers Facilities Operations Not Maintain Satisfactory Cgmp
Contract Manufacturers Ipsens Facilities Operations Not Maintain Satisfactory Contractual Obligations Commercial Commitments
Controls Procedures Conversion
Convertible Convertible Notes
Convertible Preferred Stock Convertible Securities Shall Meaning Assigned Effective Price
Convertible Shares Tercica Incs Common Stock Copy Shall Not Constitute Notice
Corporate Contracts Instruments Executed Corporate Governance Nominating Committee
Corporate Information Corporate Opportunities Waiver
Cost Product Sales Cost Sales
Costs Enforcement Counterparts
Covenants Creation Direct Financial Obligation Off-balance Sheet Arrangement
Critical Accounting Policies Estimates Currency Payments Mode Payment
D118 Tergen Defined D21 Accounting Principles Date Grant
David Mahoney Dditional Greements Acknowledgements
Dditional Nformation Dditional Nformation Roposed Ransaction Here Ind
Deadlines Reporting Information Decision-making Authority
Declaration Dividends Deferred Offering Costs
Deferred Stock Compensation Definition Electronic Transmission
Definitions Definitions Interpretation
Delaware Corporation Delaware General Corporation Law
Delaware Office Delays Omissions
Delays Performing Testing Characterization Work Increlex Delay Prevent Delegation Authority
Delivery Product Samples Shipping Charges Demand Registration Rights
Dennis Henner Phd Departure Directors Principal Officers Election Appointment
Departure Directors Principal Officers Election Appointment Certain Determination Development Costs
Development Commercial Supply Development Commercialization Governance
Development Costs Subsequent Plan Development Efforts
Development Igf-1 Combination Product Development Opt-in Rights
Development Plan General Development Responsibilities
Development Stage Limited Operating History Not Able Commercialize Development Stage Limited Operating History Not Able Successfully
Diabetes Difficulties Delays Product Manufacturing Due Advance Scheduling Requirements
Director Compensation Director Compensation Table
Director Officer Indemnification Directors
Directors Executive Officers Registrant Disadvantages
Disclosure Controls Procedures Disclosures Pertaining Stock-based Compensation Plans
Discounted Cash Flow Analysis Discuss Development-
Dispute Resolution Dissolution Liquidation Change Control
Dividend Policy Dividends
Dividends Distributions Documents Incorporated Reference
Draft Consent Order Draw Down Terms
Duration Obligations Relating Board Duration Termination Amendment
Duties Officers Duties Powers Committees
Ecitals Edemption
Edemption Xchange Ights Eduction Ithholding
Eferral Lection Eferral Lection Greement
Effect Amendment Repeal Effect Employment Service
Effect Rights Agreement Efinitions
Efinitions Capitalized Terms Not Otherwise Defined Herein Shall Ehman Rothers
Election Election Directors
Election Officers Elections Directors
Eligibility Eligibility Administration Plan
Elimination Classified Board Directors Elivery Arrant Hares
Employee Stock Purchase Plan Employees
Employment Agreements End Option Values
Endocrinology Enforcement
Entire Agreement Entry Material Definitive Agreement
Eplacement Arrant Eplacement Ote Ransfer
Eport Independent Registered Public Accounting Firm Epresentations Arranties
Epresentations Arranties Ovenants Nvestor Epresentations Arranties Ovenants Ompany
Equity Compensation Arrangements Equity Compensation Plan Information
Equity Debt Arrangements Erms Onditions
Erms Referred Hares Estimates
Estimates Reclassifications Estricted Ecurities
Estricted Tock Nit Ward Greement Etachment Ransfer Ights
Etween Evaluation Disclosure Controls Procedures
Evaluation Executive Performance Incentive Compensation Plan Evelopment Ommercialization Greement
Exact Name Registrant Specified Charter Exceptions Duty Nondisclosure
Exclusions Exclusive License
Execution Copy Executive Compensation
Executive Officer Bonuses Executive Officer Cash Compensation Arrangements
Executive Officer Long-term Incentive Compensation Executive Officer Performance Bonuses
Executive Officer Salaries Executive Officers Registrant
Exemption Ipsen Advance Notice Requirements Director Nominations Exercise Opt-in
Exercise Price Shall Mean 741 Adjusted Accordance Hereof Exhibits
Expect Continue Incur Substantial Costs Result Patent Infringement Expect Incur Substantial Costs Result Patent Infringement Litigation
Expenses Payable Advance Explanatory
Face Significant Competition Large Pharmaceutical Biotechnology Other Companies Facilities
Fact Merger Pending Harm Business Revenue Results Operations Factors Affecting Evaluation Executive Performance
Faheem Hasnain Fail Identify In-license Other Patent Rights Products Product
Fail Obtain Capital Necessary Fund Operations Unable Execute Fail Protect Intellectual Property Rights Competitors Develop Competing
Fail Unable Protect Defend Intellectual Property Rights Competitors Fair Value Financial Instruments
Fair Value Recurring Basis Federal Income Tax Consequences
Federal Income Tax Information Federal Tax Considerations
Fees Compensation Directors Fewer Children Severe Primary Igfd Estimate Ability Generate
Fewer Children Severe Primary Igfd Estimate Not Generate Fiduciary Discretion
Financial Appendix Definitions Financial Guidance
Financial Guidance 2008 Financial Outlook
Financial Planning Annual Budgets Financial Results
Financial Statement Schedules Financial Statements
Financial Statements Exhibits Financing Activities
Find Out Results Voting Annual Meeting Find Out Results Voting Special Meeting
Fixing Record Date Follow-on Public Offering
Follow-on Public Offerings Forecasting
Foreign Currency Exchange Risk Foreign Currency Translation
Form 10-k Form 10-q
Form Notice Conversion Form Right Certificate
Former Name Address Changed Since Last Report Formula Awards Outside Directors
Formula Option Grants Outside Directors Forward-looking Statements
Founders Frequency Reporting
Funding Joint Development G10 Records Retention Audit
Genentech Collaboration Genentech Combination Product Collaboration
Genentech Patents Broadly Applicable Proteins Specific Genentech Patents Specific Combination Products
Genentech Purchase Agreement Genentech Relationship
Genentechs Option General
General Rules Applicable Joint Sole Development Gne Tercicas Opt-in Right Permitted Indications
Good Faith Defined Governance
Governance Collaboration Overseen Joint Steering Committee Somatuline Jsc Governing Law
Government Disclosure Purposes Obtaining Regulatory Approval Grants Plan-based Awards
Grants Plan-based Awards Table Guarantees Indemnifications
Hares Ercica Ommon Tock Hazardous Waste
Held 2005 Held 2006
Held 2007 Held 2008
Highlights 2005 Subsequent Include Holder Desires Transfer Right Certificate
Holder Record Householding Proxy Materials
Hsr Act Icense Ollaboration Greement
Igf-1 Combination Product Development Commercialization Igf-1 Primary Igfd
Ights Tockholder Ignature Uaranteed
Ilestone Egulatory Ubmission Ime Ssuance
Immediate Release Impact Transactions Existing Stockholders-advantages Disadvantages
Impairment Long-lived Assets Implement Additional Finance Accounting Systems Procedures Controls Grow
Inability Enter Commercial Agreement Commercially Reasonable Terms Single-source Inability Enter Commercial Agreements Commercially Reasonable Terms Single-source
Inability Obtain Authority Inability Timely Transfer Alternate Single-source Manufacturer Fill-finish Increlex
Inability Timely Transfer Complete Alternate Single-source Manufacturer Bulk Inancial Ppendix
Inapplicability Income Taxes
Incorporation Reference Increlex
Increlex Drug Product Specifications Increlex Fail Achieve Market Acceptance Harm Business
Increlex Launch Increlex License
Increlex License Collaboration Agreement Increlex Mecasermin Rdna Origin Injection
Increlex Target Label Population Incur Substantial Costs Result Patent Infringement Litigation Other
Indemnification Indemnification Agreements Liability Insurance
Indemnification Contribution Event Registrable Securities Included Registration Statement Indemnification Court
Indemnification Employees Agents Indemnification Insurance
Indemnification Procedures Independence Board Directors
Independent Director Nominations Index
Index Exhibits Index Financial Statements
Indications Information Regarding Board Directors Committees
Infringement Party Rights Infringement Patents Parties
Initial Development Plan Initial Equity Investment
Initial Public Offering Insmeds Royalty Obligations Tercica Gne
Inspection Directors Inspectors Election
Insurance Intangible Assets
Intentionally Left Blank Interest Expense
Interest Other Income Net Interest Rate Risk
Interested Directors Officers Interests Officers Directors
Introduction Inventories
Investing Activities Investment Performance
Investment Policy Investment Restrictions
Investor Contact Investor Media Contact
Investor Rights Agreement Investors
Investors Rights Agreement Iplex Worldwide License Development Agreement
Ipsen Ipsen Acquire Tercica
Ipsen Collaboration Ipsen Conversions Warrant Exercise
Ipsen Purchase Agreement Ipsen Seek Influence Business Manner Contrary Goals Strategies
Ipsen Transaction Ipsen Warrant
Ipsens Conference Call Webcast Information Ipsens Forward-looking Statements
Ira Means Certain Amended Restated Investors Rights Agreement Iscellaneous
Issuer Purchases Equity Securities Ithholding Bligations
Jean-luc BĂ©lingard John Scarlett
John Scarlett Md-chief Executive Officer John Scarlett Md-president Chief Executive Officer
Joint Commercialization Committee Joint Development Committee
Joint Finance Committee Karin Eastham
Key Employee Agreement Key Employees
Key Relationships-genentech Key Relationships-insmed Incorporated
Key Relationships-ipsen Labor Rates Mutually Agreed Change Orders Per Batch
Laura Berezin Cooley Godward Llp Partner Lease Agreement
Leave Absence Legal Proceedings
Leschly Letter Regarding Interim Financial Information
License License Agreements
License Collaboration Agreement License Collaboration Agreements Related Party Transactions
License Lonza License Revenue
Licensed Trademark Licensee Hereby Grants Licensor
Licenses Bip Scras Licenses Genentech
Licenses Insmed Licenses Tercica
Licensing Agreements Licensor On-going Development
Licensor Rights Licensors On-going Development
Licensors Rights Limitation Indemnification
Limitation Liability Limitation Stockholder Rights
Limitations Certain Combination Products Limitations Effectiveness Controls
Limited Operating History Not Able Successfully Market Sell Liquidation Preference
Liquidity Maturities Guidelines List Omitted Schedules
Litigation Litigation Settlement Reached Between Tercica Genentech Insmed
Lock-up Period Long-term Debt
Lonza Manufacturing Agreement Lonza Personnel
Lose Licenses Genentech Ipsen Unable Continue Business Lose Licenses Genentech Unable Continue Business
Lost Certificates Lost Destroyed Mutilated Stolen Certificates
Maintenance Inspection Records Managements Annual Report Internal Control Over Financial Reporting
Manner Amending Manner Giving Notice Affidavit
Manufacturing Manufacturing Option
Manufacturing Services Agreement Manufacturing Services Agreements
Manufacturing Start-up Costs Market Registrants Common Equity Related Stockholder Matters Issuer
Marketability Material Modification Rights Security Holders
Media Contact Meetings
Meetings Action Committees Meetings Board Directors
Meetings Joint Steering Committee Minutes Membership
Mendment Ights Merger Not Completed Timely Manner Business Significantly Harmed
Michael Astrue Michael Parker
Milestone Payment Equity Issuance Minimum Acceptable Credit Quality
Minimum Commercial Orders Quantities Per Order Licensed Products Minutes
Miscellaneous Monthly Sales Report
Mpairment Name Person Filing Proxy Statement Other Registrant
Nclosures Ttachments Ndemnification
Ndex Efined Erms Need Others Market Commercialize Increlex Europe
Need Others Market Sell Increlex Europe Need Others Market Sell Increlex Europe Other Regions
Need Raise Additional Capital Net Income Loss Per Share
Net Loss Per Share Net Product Sales
Net Revenues New Increlex Prescriptions Increase Consecutive Quarter-
New Plan Benefits Next Generation Growth Hormone Product Candidates
Nitial Evelopment Lan Nomination Appointment Policy
Non-als Portion Set Forth Such Royalty Equal Aggregated Non-cgmp Activities
Non-disclosure Non-use Non-exclusivity Rights
Nonexclusivity Indemnification Advancement Expenses Not Ability Raise Funds Necessary Finance Repayment Convertible
Not Able Sell Products Maintain Regulatory Approval Due Not Able Sell Products Maintain Regulatory Approvals Due
Not Know Whether Planned Clinical Trials Begin Time Not Realize Anticipated Benefits Collaboration Ipsen
Not Realize Anticipated Benefits Growth Hormone Igf-1 Combination Not Realize Anticipated Benefits Proposed Transactions Ipsen
Not Receive Additional Regulatory Marketing Approvals Business Harmed Not Receive Additional Regulatory Marketing Approvals Increlex Business
Not Receive Additional Regulatory Marketing Approvals Increlex Primary Not Receive Additional Regulatory Marketing Approvals Target Labels
Not Receive Regulatory Marketing Approval Increlex Severe Primary Notes Financial Statements
Notice Notice Adjournment
Notice Electronic Transmission Notice Meetings
Notice Stockholders Meetings Notices
Nstructions Ntentionally Mitted
Ntire Greement Mendments Number 000-50461
Number Qualifications Number Term Office
Nutropin Somatropin Rdna Origin Objectives Tercicas Compensation Program
Obligations Expenses Procedures Relating Registration Officers
Officers Directors Largest Stockholders Choose Act Together They Officers Qualifications
Oint Etter Hysicians Oint Ress Elease
Olle Isaksson Phd Ommencement Ertificate
Ommon Rea Ork Once Per Annual Forecast Over Horizon
Onsolidation Erger Ale Ransfer Ssets Arning Ower Operating Activities
Operating Capital Expenditure Requirements Opt-in
Opt-in Partys Co-promotion Option Product Indication Opt-in Partys Sole Promotion Option Product Indication
Opt-in Procedure Providing Additional Information Opt-in Rights
Opt-in Rights Procedures Opt-out Process
Option Equity Investment Option Exercises Stock Vested 2006
Option Exercises Stock Vested 2007 Option Exercises Stock Vested Table
Option Grants Last Ordered
Organization Business Organizational
Ork Etter Orm Ight Ertificates
Orm Onsent Udgment Ermanent Njunction Orm Roceedings Ettlement Greement
Other Arrangements Other Benefits
Other Companies Overcome Orphan Drug Marketing Exclusivity Obtain Other Events
Other Expense Other Income Expense
Other Indemnification Other Information
Other Matters Other Officers
Other Offices Otice Djustments
Otices Outstanding Equity Awards 2006
Outstanding Equity Awards 2007 Overall Effect Proposal
Overview Overview Opt-ins Opt-outs
Ownership Intellectual Property Joint Trademarks Patent Rights Paragraph Shall Amended Restated Read Entirety Follows
Part Part Other Information
Party Intellectual Property Patent Enforcement Rights
Patent Filings Prosecution Patents Proprietary Rights
Patents Solely Owned Paying Proxy Solicitation
Payment Payments
Pending Fda Guidance Tercica Intends Initiate Phase Clinical Per Batch Price Calendar 2006 Defined Change Order
Per Share Paid Cash Performance Measurement Comparison
Performance Units Shares Permitted Indebtedness
Permitted Liens Place Meeting
Place Meetings Place Meetings Telephone
Plain Royalty Rate Plan
Policies Procedures Review Related Party Transactions Potential Igf-1 Combination Product Aghd
Potential Igf-1 Combination Product Short Stature Potential Payments Termination Change Control
Power Attorney Power Indemnify Actions Suits Proceedings Other Those Right
Power Indemnify Actions Suits Proceedings Right Corporation Powers
Pre Opt-in Development Costs Post Pre-approval Policies Procedures
Preferred Stock Preparation Commercialization Plans Annual Budgets
Preparation Development Plans Annual Budgets President
Pricing Principal Accountant Fees Services
Principles Reporting Proceeds
Proceeds Additional Securities Issued Connection Repayment Convertible Notes Proceeds Registered Securities
Product Intellectual Property Product Liability Indemnification Insurance
Product Liability Lawsuits Brought Against Incur Substantial Liabilities Product Lost Damaged Manufacturing Storage Shipment Business Suffer
Product Prices Product Specifications
Product Test Methods Product Updates
Products Fail Achieve Market Acceptance Harm Business Proforma Balance Sheet
Promotional Advertising Expenses Properties
Property Equipment Proposed Acquisition Affiliates Ipsen
Proposed Transaction Ipsen Proposed Transaction Ipsen Completed Resulting Relationship Limit Ability
Proposed Transaction Ipsen Completed Stockholders Experience Immediate Substantial Prosecution Patents
Provision Income Taxes Provision Know-how Coordination Manufacturing Supply
Provision Opt-in Information Proxies
Public Announcements Sec Filings Publication
Publicity Other Public Disclosures Purchase Accounting
Purchase Sale Common Stock Purchase Sale Initial Securities
Purchase Sale Shares Purchaser
Purpose Purposes
Qualitative Quantitative Disclosures Market Risk Quality Agreement
Quantitative Qualitative Disclosures Market Risk Quarterly Financial Data-unaudited
Quorum Ratification Selection Independent Registered Public Accounting Firm
Reasons Effect Supermajority Charter Amendments Reasons Stockholder Approval
Receiving Materials Recent Accounting Development
Recent Accounting Pronouncement Recent Accounting Pronouncements
Recent Highlights Recent Highlights Updates
Recitals Reclassifications
Recommends Vote Proposal Reconstitution Office President
Record Date Purposes Other Notice Voting Record Date Stockholder Notice Voting Giving Consents
Records Reduction Elimination Supermajority Voting Requirement
Refutes Competitors Assertions- Registered Office
Registered Public Accounting Firm Registrants Telephone Number Including Area Code
Registrants Telephone Number Including Area Code 650 624-4900 Registration Procedures
Registration Rights Registration Rights Agreement
Regular Meetings Regulated Purchase Period
Regulatory Affairs Reimbursement
Reimbursement Development Costs Prior Genentech Opt-in Reimbursement Not Available Increlex Diminish Sales Impact Ability
Reimbursement Products Slow Not Available Levels Expect Resulting Related Party Transactions
Releases Waiver Rely Certain Cases Single-source Sole-source Materials Suppliers Manufacture
Rely Solely Single-source Parties Manufacture Testing Storage Distribution Remainder Page Intentionally Left Blank
Remainder Page Intentionally Left Blank Signature Follows Removal
Removal Directors Removal Directors Without Cause
Removal Officers Removal Resignation Officers
Report Audit Committee Board Directors Report Independent Registered Public Accounting Firm
Reporting Information Reports
Reports Exchange Financial Information Representation Counsel Each Party Acknowledges Been Represented Independent
Representation Shares Other Corporations Representations Warranties
Representations Warranties Covenants Representations Warranties Covenants Investor
Representations Warranties Genentech Representations Warranties Ipsen
Representations Warranties Other Provisions Representatives Ernst Young Llp Present Special Meeting
Required Copy Shall Not Constitute Notice Research Development
Research Development Costs Research Development Expenses
Research Product Development Costs Resignation
Resignation Appointment Directors Resignation Vacancies
Responsibilities Restricted Stock
Restricted Stock Purchases Early Exercise Options Restricted Stock Unit Awards Option
Restricted Stock Units Restriction Block Transfers
Results Not Meet Analysts Forecasts Expectations Stock Price Results Operations
Results Operations Financial Condition Return Certificates
Revenue Expenses Revenue Recognition
Revenues Reverse Stock Split
Revised Drug Substance Pricing Rice Ased Nti Ilution Djustment Onversion
Richard King Richard King-president Chief Operating Officer
Rigger Lip Ver Ights Right Genentech Access Regulatory Authority Documentation
Right Indemnification Right Negotiation Other Products
Right Offer Right Tercica Access Genentech Product Technology Regulatory Authority
Rights Agreement Rights Granted Tercica Gne
Risk Factors Risk Securities Class Action Litigation
Risks Related Common Stock Rohibited Ses Ider
Role Board Role Compensation Committee Tercicas Board Directors
Role Igf-1 Glucose Metabolism Role Igf-1 Growth Metabolism
Romotion Greement Erms Onditions Ross Clark Phd
Royalties Other Named Patient Sales Pursuant Off-label Royalties Payable Genentech
Royalties Payable Tercica Royalty Payments
Royalty Revenue Safe Harbor Statement
Safe-harbor Statement Safety Reporting Quality Agreement
Sales Marketing Sales Report
Sales Reports Sales Tracking Methodology
Sarbanes-oxley Act 2002 Schedule
Schedule 14a Schedule Executive Officer Receipents
Scientific Background-acromegaly Scientific Background-adult Growth Hormone Deficiency Aghd
Scientific Background-short Stature Scope Confidential Information
Seal Secretary
Sections Shall Amended Restated Read Entirety Follows Securities Exchange Act 1934
Securities Registered Pursuant Act Security Ownership Certain Beneficial Owners Management Related Stockholder
Security Procedures See Accompanying Notes
Seeking Approval Certificate Incorporation Amendments Bylaw Selection Registration Protection Joint Trademarks
Selling General Administrative Expenses Senior Convertible Promissory
Senior Credit Facility Settlement Agreement
Settlement License Development Agreement Settlement Payments Between Parties
Severability Severance Change Control Benefits
Shall Amended Include Following Sentence Immediately 2004 Shall Amended Restated Read Entirety Follows
Shares Reserved Issuance Shares Subject Amended 2004 Plan
Shares Subject Plan Sharing Operating Profit Product Opt-in Indication
Shelf Registration Short Stature
Short Stature Primary Igfd Signature
Signature Page Follow Signature Page Follows
Signature Page Settlement License Development Agreement Signatures
Signatures Appear Following Page Significant Accounting Policies
Size Board Sole Development Party Opt-in Rights
Somatuline Depot Somatuline License
Somatuline License Collaboration Agreement Sources Liquidity
Special Designation Certificates Special Meeting
Special Meetings Special Meetings Notice
Specific Performance Injunctive Other Equitable Relief Specifications Compliance Cgmp Shall Set Forth Technical Agreement
Ssuance Tock Onversion Ssue Ecurities
Ssue Ight Ertificates Standard Form Release Provisions
Standstill Period State Other Jurisdiction Incorporation
Stephen Rosenfield Stephen Rosenfield-executive Vice President Legal Affairs General Counsel
Stipulated Final Judgment Stipulated Findings Fact Conclusions Law
Stipulated Order Permanent Injunction Stock Appreciation Rights
Stock Based Compensation Stock Certificates Partly Paid Shares
Stock Compensation Stock Option Awards
Stock Option Grants Exercises Stock Options
Stock Options Granted Non-employees Stock Plan
Stock Plan 2002 Executive Stock Price Volatile Investment Decline Value
Stock Purchase Agreement Shall Meaning Assigned Paragraph Warrant Stock Purchase Master Transaction Agreement 2006 Etween
Stock Purchase Rights Stock Sales
Stock-based Award Modification Stock-based Compensation
Stockholder Action Written Consent Stockholder Action Written Consent Without Meeting
Stockholder Approval Stockholder Communications Board Directors
Stockholder Proposals Due Next Annual Meeting Stockholder Proposals Due Tercicas 2007 Annual Meeting Stockholders
Stockholder Record Shares Registered Name Stockholder Rights Plan
Stockholder Rights Plan Anti-takeover Provisions Charter Documents Delaware Stockholders
Stockholders Equity Stockholders Right Call Special Meeting
Strategic Collaboration Agreement Endocrinology Strategic Collaboration Ipsen
Strategic Planning Committee Strategic Planning Committee Charter
Strategy Subject Fraud Abuse Similar Laws Regulations Failure Comply
Subject Genentechs Option Rights Respect Commercialization Increlex Diabetes Sublicenses Exercise Licensed Rights Parties
Submission Matters Vote Security Holders Subordinate Officers
Subscriptions Subsequent Development Plan
Subsequent Development Plans Other Products Subsequent Development Plans Product Improvements Combination Products
Subsequent Event Subsequent Events
Substantial Sales Shares Impact Market Price Common Stock Summary Cash Certain Other Compensation
Summary Compensation Table Summary Purchase Agreement Other Transaction Documents
Summary Rights Agreement Summary Significant Accounting Policies
Supplied Materials Consumables Equipment Suraypharm Ipsen
Survival Indemnification Advancement Expenses Table Calculating Aggregated Royalty Amount
Table Calculating Als Credit Table Contents
Taxes Technology Transfer Engineering
Template Per Type Product Sold Tercica
Tercica Announces Agreement Genentech Worldwide Growth Hormone Igf-1 Tercica Announces Financing
Tercica Entering Transaction Ipsen Tercica Forward Looking Statements
Tercica Genentech Indications Non-tercica Tercica Genentech Opt-in Rights
Tercica Genentechs Opt-in Rights Tercica Inc
Tercica Inc Announces Follow-on Offering Common Stock Tercica Increlex
Tercica Names Michael Astrue Board Directors Tercica Provides Nda Update Appoints Chief Medical Officer
Tercica Reports 2004 Financial Results Tercica Reports 2005 Financial Results
Tercica Reports 2008 Financial Results Tercica Reports Financial Results
Tercica Reports Year-end 2007 Financial Results Tercica Safe Harbor Statement
Tercica Seeking Stockholder Approval Adoption Rights Agreement Set Tercica Seeking Stockholder Approval Amendment Tercicas Amended Restated
Tercica Seeking Stockholder Approval Amendments Tercicas Amended Restated Tercica Seeking Stockholder Approval Issuance Securities Ipsen Set
Tercicas 2006 Compensation Program Tercicas Conference Call Webcast Information
Tercicas Executive Compensation Program Tercicas Forward Looking Statements
Tercicas Gnes Right Terminate Term
Term Office Term Overview Termination Rights
Term Plan Term Royalty Obligations
Term Termination Termination
Termination Agreement Entirety Insmed Tercicas Gnes Material Breach Termination Agreement Permitted Indication Insmed
Termination Material Definitive Agreement Terms Agreement
Terms Conditions Employment Terms Options
Terms Performance Shares Units Terms Restricted Stock Awards
Terms Restricted Stock Unit Awards Terms Stock Appreciation Rights
Terms Stock Purchase Rights Third-party Clinical Research Organizations Not Perform Acceptable Timely
Thomas Silberg Thomas Wiggans
Thorsten Von Stein Phd Thorsten Von Stein Phd- Senior Vice President Clinical
Thorsten Von Stein Phd-chief Medical Officer Senior Vice Timothy Lynch
Title Class Titles Subtitles
Tock Lan Trade Accounts Receivable
Trade Guidelines Transfer Shares
Transferability Awards Treasurer
Treasury Advisor Treatment Short Stature Caused Primary Igf-1 Deficiency
Umber Estricted Tock Nits Hares Unable Attract Retain Additional Qualified Personnel Ability Commercialize
Unable Attract Retain Additional Qualified Personnel Ability Market Unable Complete Proposed Transaction Ipsen Timely Manner Face
Unable Establish Direct Sales Force United States Business Unable Establish Fda Rhigf-1 Comparable Produced Genentech Ability
Unable Manage Expected Growth Not Able Implement Business United States
Unregistered Sales Equity Securities Unregistered Sales Equity Securities Proceeds
Unvested Share Exercise Notice Up-front Payments
Updates Urrent Onference Oom Ates
Urther Djustments Onversion Rice Vacancies
Vacancies Offices Validation Meetings Waiver Notice Consent
Valuation Convertible Related Derivative Valuation Derivative Instruments
Valuation Warrants Variable Amount Notification Dilution
Vents Efault Vice Presidents
Vote Vote Annual Meeting
Vote Required Board Recommendation Vote Special Meeting
Vote Telephone Internet Available Votes
Votes Counted Votes Needed Approve Each Proposal
Voting Voting Agreements
Waiver Notice Warrant
Warrant Issued Ipsen Warrant Shares Shall Meaning Assigned Paragraph Xercise
Warrants Warranty
What Mean Receive Proxy Card What Proposals Not Approved
What Quorum Requirement What Return Proxy Card Not Make Specific Choices
What Voting Whereas Parties Avecia Agreed Date Hereof Enter Certain
Withholding Worldwide Pre-approval Iplex Sales
Xchange Xcluded Ndications
Xercisability Ights Xercise Ights Urchase Rice Xpiration Ate
Xhibit 1014c Xhibit 1014d
Xhibit 108b Xhibit Ights Greement
Xhibits Xiiixiv
Yearly Sales Reports 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki